Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT04929600

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04929600
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04929600. Randomized; quadruple masking; primary purpose treatment. Start 2021-11-28 (actual); primary completion 2023-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy.
Condition
Hypertension
Condition
Left Ventricular Hypertrophy
Intervention (Drug)
sacubitril/valsartan
Intervention (Drug)
Amlodipine
Lead sponsor
Shanghai Jiao Tong University School of Medicine (class: other)

Record details

Record id
cardio:ct-nct04929600
Content hash
5bf03b1a5ab7b535d87bcbf8e462c076fc7a7455720ae74b8e91d07db2523dff